Akut Migren Tedavisinde Propofol ve Klorpromazin: Prospektif Randomize Bir Çalışmadan Elde Edilen Bulgular

Öz

Amaç: Bu çalışma, akut migren ataklarının yönetiminde propofol ve klorpromazinin etkinliğini karşılaştırmayı ve acil serviste (AS) migren tedavisinin optimize edilmesine katkıda bulunmayı amaçlamıştır. Yöntemler: Bu prospektif, randomize gözlemsel çalışmada, yaşları 18-65 arasında değişen 180 migren hastası iki gruba randomize edildi. Bir gruba her 10 dakikada bir 10 mg (maksimum 50 mg’a kadar) propofol, diğer gruba ise her 20 dakikada bir 12.5 mg (maksimum 37.5 mg’a kadar) klorpromazin uygulandı. Ağrı, görsel analog skala (VAS) kullanılarak her 10 dakikada bir değerlendirildi. Bulgular: Başlangıçtaki ortalama VAS skorları propofol grubunda 8,24 ± 1,72, klorpromazin grubunda ise 8,83 ± 1,43 idi. Propofol grubunda VAS skorları 10., 20. ve 30. dakikalarda sırasıyla 5,19 ± 2,79, 2,66 ± 2,91 ve 1,25 ± 2,14 birim azaldı. Klorpromazin grubunda bu azalmalar sırasıyla 4,82 ± 2,99, 2,50 ± 2,93 ve 1,03 ± 2,20 birim olarak ölçüldü. 60. dakikada toplam VAS azalması propofol grubunda 25,00 ± 12,25, klorpromazin grubunda ise 23,10 ± 11,40 olarak belirlendi ve gruplar arasında istatistiksel olarak anlamlı bir fark saptanmadı. Sonuç: Propofol, AS’de akut migren yönetiminde klorpromazin kadar etkiliydi ve benzer bir etki başlama süresi ile daha iyi bir yan etki profili gösterdi.

Anahtar Kelimeler

• migren atağı
• propofol
• klorpromazin
• akut migren tedavisi

Propofol vs. Chlorpromazine for Acute Migraine Treatment: Insights from a Prospective Randomized Trial

Abstract

Objective: This study aimed to compare the efficacy of propofol and chlorpromazine in managing acute migraine attacks and to contribute to optimizing the treatment of patients with migraine in the ED. Methods: This prospective, randomized observational study included 180 migraine patients aged 18–65 presenting to the ED. Patients were randomized into two groups: one received propofol (10 mg every 10 minutes, up to 50 mg), and the other received chlorpromazine (12.5 mg every 20 minutes, up to 37.5 mg). Pain was monitored every 10 minutes using a visual analog scale (VAS). Results: At admission, the mean VAS score was 8.24 ± 1.72 in the propofol group and 8.83 ± 1.43 in the chlorpromazine group. In the propofol group, the VAS score decreased by 5.19 ± 2.79, 2.66 ± 2.91, and 1.25 ± 2.14 units at the 10th, 20th, and 30th minutes, respectively. In the chlorpromazine group, the VAS score decreased by 4.82 ± 2.99, 2.50 ± 2.93, and 1.03 ± 2.20 units at the 10th, 20th, and 30th minutes, respectively. By the 60th minute, the total VAS reduction was 25.00 ± 12.25 in the propofol group and 23.10 ± 11.40 in the chlorpromazine group. Although pain reduction initially occurred more rapidly in the chlorpromazine group, there was no statistically significant difference between the groups at the 60-minute mark. Conclusion: Propofol was as effective as chlorpromazine for treating migraines in the ED, with a comparable onset of action and a better side-effect profile.

Keywords

• migraine attack
• propofol
• chlorpromazine
• acute migraine attack

Kaynakça

1. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain.1983;16(1):87-101. doi:10.1016/0304-3959(83)90088-X.
2. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet. 2017;389(10064):e1]. Lancet. 2016;388(10053):1603-1658. doi:10.1016/S0140-6736(16)31460-X.
3. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267(1):64-69.
4. Baykan B. Başağrıları. In: Nöroloji. 2nd ed. İstanbul: Nobel Tıp Kitabevi; 2011:373-393.
5. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202.
6. Boran HE, Bolay H. Migren patofizyolojisi. Nöro Psikiyatri Arşivi. 2013;50(1):1-7. doi:10.4274/npa.y7251.
7. Penfield W. Dural headache and innervation of the dura mater. Arch Neurol Psychiatry. 1940;44(1):43. doi:10.1001/archneurpsyc.1940.02280070051003.
8. Ray BS, Wolff HG. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg. 1940;41(4):813-856.

9. Mayberg MR, Zervas NT, Moskowitz MA. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol. 1984;223(1):46-56. doi:10.1002/cne.902230105.
10. Wirth FP Jr, Van Buren JM. Referral of pain from dural stimulation in man. J Neurosurg. 1971;34(5):630-642. doi:10.3171/jns.1971.34.5.0630.
11. Singer AB, Buse DC, Seng EK. Behavioral treatments for migraine management: useful at each step of migraine care. Curr Neurol Neurosci Rep. 2015;15(4):14. doi:10.1007/s11910-015-0533-5.
12. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2000;56(1):142]. Neurology. 2000;55(6):754-762. doi:10.1212/wnl.55.6.754.
13. Rizzoli PB. Acute and preventive treatment of migraine. Continuum (Minneap Minn). 2012;18(4):764-782. doi:10.1212/01.CON.0000418641.45522.3b.
14. Krusz JC, Scott V, Cagle J. Effectiveness of IV therapy in the headache clinic for refractory migraines. Eur J Neurol Suppl. 2005;12:78.
15. Zarifoglu M, Siva A, Hayran O, Selekler K, Idiman F, Sanca Y. An epidemiologic study of headache in Turkey: a nationwide survey. Neurology. 1998;50(4).
16. Özdedmir G, Aygul R, Demir R, et al. Migraine prevalence, disability, and sociodemographic properties in the eastern region of Turkey: a population-based door-to-door survey. Turk J Med Sci. 2014;44(4):624-629.
17. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349. doi:10.1212/01.wnl.0000252808.97649.21.
18. Soleimanpour H, Ghafouri RR, Taheraghdam A, et al. Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double-blind randomized clinical trial. BMC Neurol. 2012;(12):114. doi:10.1186/1471-2377-12-114.
19. Iserson KV. Parenteral chlorpromazine treatment of migraine. Ann Emerg Med. 1983;12(12):756-758. doi:10.1016/s0196-0644(83)80251-0.
20. McEwen JI, O'Connor HM, Dinsdale HB. Treatment of migraine with intramuscular chlorpromazine. Ann Emerg Med.1987;16(7):758-763. doi:10.1016/s0196-0644(87)80569-3.
21. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141-148. doi:10.1016/s0736-4679(02)00502-4.
22. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med. 1989;18(4):360-365. doi:10.1016/s0196-0644(89)80570-0.
23. Bell R, Montoya D, Shuaib A, Lee MA. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 1990;19(10):1079-1082. doi:10.1016/s0196-0644(05)81507-0.
24. Kelly AM, Ardagh M, Curry C, D'Antonio J, Zebic S. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. J Accid Emerg Med. 1997;14(4):209-211. doi:10.1136/emj.14.4.209.
25. Mariani PJ. Adverse reactions to chlorpromazine in the treatment of migraine. Ann Emerg Med. 1988;17(4):380-381. doi:10.1016/s0196-0644(88)80802-3.
26. Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache.2000;40(3):224-230. doi:10.1046/j.1526-4610.2000.00032.x.
27. Folkerts H. Migraine after electroconvulsive therapy. Convuls Ther. 1995;11(3):212-215.
28. Drummond-Lewis J, Scher C. Propofol: a new treatment strategy for refractory migraine headache. Pain Med.2002;3(4):366-369. doi:10.1046/j.1526-4637.2002.02034.x.
29. Mosier J, Roper G, Hays D, Guisto J. Sedative dosing of propofol for treatment of migraine headache in the emergency department: a case series. West J Emerg Med. 2013;14(6):646-649. doi:10.5811/westjem.2013.7.18081.
30. Ward DI, Mulcahy R, Bailey P, Morgan D. Use of intravenous propofol in the treatment of migraine headache. Emerg Med Australas. 2013;25(6):619. doi:10.1111/1742-6723.12145.